Guidance for industry : Q3B(R2) impurities in new drug products.

Bibliographic Details
Corporate Authors:	Center for Drug Evaluation and Research (U.S.), Center for Biologics Evaluation and Research (U.S.), International Conference on Harmonisation
Format:	Government Document Conference Proceeding eBook
Language:	English
Published:	Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, [2006]
Subjects:	Drug development > Government policy > United States. Drug adulteration > Government policy > United States.
Online Access:	https://purl.fdlp.gov/GPO/LPS113762

Available Online